Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Open access
Gandhi, Shiv, Klein, Jonathan, Robertson, Alexander J., Peña-Hernández, Mario A., Lin, Michelle J., Roychoudhury, Pavitra, Lu, Peiwen, Fournier, John, Ferguson, David, Mohamed Bakhash, Shah A. K., Catherine Muenker, M., Srivathsan, Ariktha, Wunder, Elsio A., Kerantzas, Nicholas, Wang, Wenshuai, Lindenbach, Brett, Pyle, Anna, Wilen, Craig B., Ogbuagu, Onyema, Greninger, Alexander L., Iwasaki, Akiko, Schulz, Wade L., Ko, Albert I.·2022·Nature Communications

Abstract

SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase, which was not present in pre-treatment specimens. In vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir IC 50 but resulted in a fitness cost in the absence of remdesivir. Sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. Although the fitness cost observed in vitro may limit the risk posed by E802D, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-29104-y

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 305

Metadata

Authors
Gandhi, S., Klein, J., Robertson, A. J., Peña-Hernández, M. A., Lin, M. J., Roychoudhury, P., Lu, P., Fournier, J., Ferguson, D., Mohamed Bakhash, S. A. K., Catherine Muenker, M., Srivathsan, A., Wunder, E. A., Kerantzas, N., Wang, W., Lindenbach, B., Pyle, A., Wilen, C. B., Ogbuagu, O., Greninger, A. L., Iwasaki, A., Schulz, W. L., & Ko, A. I.
Venue
Nature Communications
Published
2022-03-17
Volume
13
Issue
1
Pages
1547-1547
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4226163566
Cited by
305
References
29
FWCI
31.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. https://app.cochat.ai/papers/10.1038/s41467-022-29104-y
The paper
Gandhi, S., Klein, J., Robertson, A. J., Peña-Hernández, M. A., Lin, M. J., Roychoudhury, P., Lu, P., Fournier, J., Ferguson, D., Mohamed Bakhash, S. A. K., Catherine Muenker, M., Srivathsan, A., Wunder, E. A., Kerantzas, N., Wang, W., Lindenbach, B., Pyle, A., Wilen, C. B., Ogbuagu, O., . . . Ko, A. I. (2022). De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications. https://doi.org/10.1038/s41467-022-29104-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.